Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes

@article{Sokol2017UseOA,
  title={Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes},
  author={E. Sokol and M. Karram},
  journal={Menopause},
  year={2017},
  volume={24},
  pages={810–814}
}
Objectives: To assess safety and efficacy of a fractional CO2 laser therapy for the treatment of genitourinary syndrome of menopause (GSM) with follow-up to 1 year posttreatment. [...] Key Method Methods: Women presenting with GSM and meeting inclusion criterion were enrolled. Visual Analog Scales were used to grade vaginal pain, burning, itching, dryness, dyspareunia, and dysuria. Dilators were used to rate vaginal elasticity at baseline and at each follow-up visit.Expand
Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results
TLDR
Laser therapy may provide significant improvement and/or absence of GSM symptoms up to 12 months follow-up, irrespectively to the number of laser therapies applied, in short and long-term follow- up. Expand
Prospective Study of Fractional Carbon Dioxide Laser Therapy for Symptoms of Genitourinary Syndrome of Menopause: One-Year Follow-Up
TLDR
Clinically significant improvement was noted in subjective and objective assessments of GSM, and was sustained for 1 year following pixelated CO 2 laser therapy. Expand
Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors.
TLDR
Fractional CO2 laser therapy is feasible in gynecologic cancer survivors, with preliminary evidence of safety and improvement in sexual function compared with sham treatment, according to a pilot, multi-institutional randomized sham-controlled trial of women with Gynecologic cancers with dyspareunia and/or vaginal dryness. Expand
Safety evaluation of fractional CO2 laser treatment in post-menopausal women with vaginal atrophy: A prospective observational study.
TLDR
Fractional CO2 laser for treatment of VVA seems a safe therapeutic option, and patients were highly satisfied, and they would repeat laser treatment. Expand
Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy.
TLDR
In BC survivors with GSM, the total and individual domain scores of the FSFI and the FSDS-R improved after fractional CO2 laser therapy, indicating less sexually related distress. Expand
Long-term reliability of fractioned CO2 laser as a treatment for vulvovaginal atrophy (VVA) symptoms
TLDR
Long-term data showed that the improvement of vaginal health may continue up to 24 months after fractional CO2 laser treatment although between 18 and 24  Months benefits decline, and approximately 80% of women decide to start a new treatment cycle of laser applications. Expand
Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors
TLDR
Fractional CO2 laser treatment for breast cancer survivors with dyspareunia and/or vaginal dryness is feasible and appears to reduce GSM symptoms across treatment and follow-up. Expand
Treatment to External Labia and Vaginal Canal With CO2 Laser for Symptoms of Vulvovaginal Atrophy in Postmenopausal Women
TLDR
Fractional CO2 laser treatments were well tolerated and were associated with improvement in vaginal health and amelioration of symptoms of VVA, and correlated with clinical restoration of vaginal hydration and pH to premenopausal levels. Expand
The Effect of the CO2 Fractional Laser or Premarin Vaginal Cream on Improving Sexual Function in Menopausal Women: A Randomized Controlled Trial.
TLDR
It seems that the fractional CO2 laser may be more effective than hormonal therapy in improving sexual function in postmenopausal women. Expand
A Double-Blind Randomized Sham-Controlled Trial to Evaluate the Efficacy of Fractional Carbon Dioxide Laser Therapy on Genitourinary Syndrome of Menopause.
TLDR
This study was underpowered to draw conclusions regarding the efficacy of fractional CO2 laser therapy in the treatment of GSM, but did observe improvements in the sham-arm to suggest a possible placebo contribution. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy
TLDR
The data suggest that the fractional CO2 laser is effective and safe for treatment of the symptoms associated with GSM. Expand
A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study
TLDR
A 12-week treatment with the fractional CO2 laser was feasible and induced a significant improvement of VVA symptoms by ameliorating vaginal health in postmenopausal women. Expand
Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser.
TLDR
Thermo-ablative fractional CO2 laser could be a safe, effective and feasible option for the treatment of VVA symptoms in post-menopausal women. Expand
Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study
TLDR
Ospemifene was shown to be effective and well tolerated for the treatment of the symptoms of vaginal dryness and dyspareunia associated with vulvovaginal atrophy over and above the use of provided lubricants. Expand
Ablative fractionated CO2, laser resurfacing for the neck: prospective study and review of the literature.
TLDR
AFP was both safe and effective for the treatment of neck laxity, rhytids and skin texture and the degree of improvement observed in wrinkling, texture and laxity after AFP coupled with the benign side effect profile has not been reported with previous trials of ablative laser resurfacing of the neck. Expand
Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
TLDR
Results of Phase III clinical trials showed that ospemifene significantly improved the vaginal maturation index, decreased vaginal pH, and decreased severity of the self-identified most bothersome symptom (dyspareunia or vaginal dryness) compared to placebo. Expand
Novel Minimally Invasive VSP Er:YAG Laser Treatments in Gynecology
TLDR
Based on these initial clinical results, the new IntimaLaseTM and IncontiLase TM gynecological treatments are promising to become a minimally invasive solution of choice for many women suffering from vaginal relaxation syndrome or stress urinary incontinence. Expand
Vulvovaginal symptoms prevalence in postmenopausal women and relationship to other menopausal symptoms and pelvic floor disorders
TLDR
Vulvovaginal symptoms are common and present in over 50% of postmenopausal women and were associated with increased co-occurrence of specific pelvic floor disorders, including pelvic organ prolapse, anal incontinence to solid stool, and dysuria. Expand
Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
TLDR
Significant barriers to treatment include lack of knowledge about VVA, reluctance to discuss symptoms with HCPs, safety concerns, inconvenience, and inadequate symptom relief from available treatments. Expand
...
1
2
3
...